Merck & Company news
×Merck & Company
23.12.21
Merck & Company
Philippines has approved the emergency use of Merck & Co's oral medication to treat COVID-19. The drug is indicated for adult patients in whom the disease is likely to become severe.
Philippines has approved the emergency use of Merck & Co's oral medication to treat COVID-19. The drug is indicated for adult patients in whom the disease is likely to become severe.
Source: 
reuters.com
reuters.com
0
0
22.12.21
Merck & Company
France has canceled a pre-order for 50,000 doses of Merck & Co's molnupiravir to treat COVID-19. The French Ministry of Health attributed its decision to evidence that the drug reduces the risk of hospitalization or death by only 30%. Instead of molnupiravir, France ordered Pfizer's rachlorovid, which demonstrated a 90% reduction in that risk.
France has canceled a pre-order for 50,000 doses of Merck & Co's molnupiravir to treat COVID-19. The French Ministry of Health attributed its decision to evidence that the drug reduces the risk of hospitalization or death by only 30%. Instead of molnupiravir, France ordered Pfizer's rachlorovid, which demonstrated a 90% reduction in that risk.
Source: reuters.com
reuters.com
0
0
22.12.21
Merck & Company
U.K. government has ordered another 1.75 million courses of oral molnupiravir COVID-19 treatment from Merck & Co. and Ridgeback Biotherapeutics. Previously, the U.K. purchased 480,000 courses of the drug. Merck & Co. already has pre-delivery agreements for molnupiravir with the governments of more than 30 countries.
U.K. government has ordered another 1.75 million courses of oral molnupiravir COVID-19 treatment from Merck & Co. and Ridgeback Biotherapeutics. Previously, the U.K. purchased 480,000 courses of the drug. Merck & Co. already has pre-delivery agreements for molnupiravir with the governments of more than 30 countries.
Source: 
merck.com
merck.com
0
0
15.12.21
Merck & Company
Merck has received European Commission approval for the VAXNEUVANCE vaccine. The drug is designed to prevent pneumonia and other invasive diseases caused by pneumococci in people 18 years of age and older. VAXNEUVANCE was also approved by the FDA in July 2021.
Merck has received European Commission approval for the VAXNEUVANCE vaccine. The drug is designed to prevent pneumonia and other invasive diseases caused by pneumococci in people 18 years of age and older. VAXNEUVANCE was also approved by the FDA in July 2021.
Source: merck.com
merck.com
0
0
07.12.21
Merck & Company
Merck & Co. has agreed with Thermo Fisher Scientific to produce molnupiravir, Merck's oral drug for CVOD-19. The drug will be shipped from Thermo Fisher's Ontario site to Canada and the United Kingdom, as well as markets in the European Union, Asia-Pacific and Latin America. Previously, the Canadian government ordered 500,000 courses of molnupiravir with del...
Merck & Co. has agreed with Thermo Fisher Scientific to produce molnupiravir, Merck's oral drug for CVOD-19. The drug will be shipped from Thermo Fisher's Ontario site to Canada and the United Kingdom, as well as markets in the European Union, Asia-Pacific and Latin America. Previously, the Canadian government ordered 500,000 courses of molnupiravir with del...
Source: reuters.com
reuters.com
0
0
01.12.21
Merck & Company
FDA Antimicrobial Committee has recommended approval for the emergency use of the oral drug molnupiravir, developed by Merck & Co. and Ridgeback. The drug is recommended for treatment of mild to moderate COVID-19 in adults at high risk of progression to severe disease.
FDA Antimicrobial Committee has recommended approval for the emergency use of the oral drug molnupiravir, developed by Merck & Co. and Ridgeback. The drug is recommended for treatment of mild to moderate COVID-19 in adults at high risk of progression to severe disease.
Source: merck.com
merck.com
0
0
30.11.21
Merck & Company
The Merck & Company Board of Directors announced a quarterly dividend of $0.69 per share. The last day to buy securities to receive the dividend is December 13, 2021. The annual dividend yield may reach 3.51%.
The Merck & Company Board of Directors announced a quarterly dividend of $0.69 per share. The last day to buy securities to receive the dividend is December 13, 2021. The annual dividend yield may reach 3.51%.
Source: merck.com
merck.com
0
0
26.11.21
Merck & Company
Merck & Co. and Ridgeback Biotherapeutics have reported more complete data from a study of the antiviral drug molnupiravir as a treatment for COVID-19. An analysis of information from all 1,433 study participants showed that molnupiravir reduced the risk of hospitalization or death by 30%, from 9.7% to 6.8%. Previous interim data showed a 48% risk reduction...
Merck & Co. and Ridgeback Biotherapeutics have reported more complete data from a study of the antiviral drug molnupiravir as a treatment for COVID-19. An analysis of information from all 1,433 study participants showed that molnupiravir reduced the risk of hospitalization or death by 30%, from 9.7% to 6.8%. Previous interim data showed a 48% risk reduction...
Source: merck.com
merck.com
0
0
22.11.21
Merck & Company
Merck & Co. has completed its $11.5 billion acquisition of Acceleron Pharma, which specializes in the development of protein therapies to treat cancer, as well as the discovery and development of drugs for rare hematological and lung diseases.
Merck & Co. has completed its $11.5 billion acquisition of Acceleron Pharma, which specializes in the development of protein therapies to treat cancer, as well as the discovery and development of drugs for rare hematological and lung diseases.
Source: merck.com
merck.com
0
0
10.11.21
Merck & Company
Japanese government will purchase 1.6 million courses of the oral COVID-19 drug Molnupiravir from Merck and Ridgeback Biotherapeutics, subject to approval from the Japanese Pharmaceutical and Medical Device Agency. The cost of the batch will be about $1.2 billion.
Japanese government will purchase 1.6 million courses of the oral COVID-19 drug Molnupiravir from Merck and Ridgeback Biotherapeutics, subject to approval from the Japanese Pharmaceutical and Medical Device Agency. The cost of the batch will be about $1.2 billion.
Source: merck.com
merck.com
0
0
English (US) 